Navigation Links
ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer

Lung cancer, the header among all forms of cancer, is avenged now by the new proven effective ZD1839.

It has been shown that ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, has confirmed, durable responses and safety in patients with advanced non-small cell lung cancer (NSCLC) as monotherapy and in combination with standard chemotherapy agents after segmental scrutinization in two different studies.

Vincent Miller, MD, of Memorial Sloan-Kettering Cancer Center in New York and the principal investigator of the first study said, "It is hoped that our study will be a prelude to better outcomes for NSCLC patients in the near future." No novel toxicities were seen with ZD1839 treatment in combination with standard chemotherapy.

In a second study, which addressed intermittent dosing of ZD1839 in Japanese patients with advanced lung cancer, more than 20% of patients showed partial responses to ZD1839 between 1 and 11 months.

With such promising results, researchers are now working on whether this drug can be used for other forms of cancer as well.
'"/>




Page: 1

Related medicine news :

1. Study Proves That MMR Vaccine Is Not Connected To Autistic Babies
2. Pilot Study Proves Home Abortions ‘Safe’
3. Many Nonprescription Cough Medicines Proves Ineffective
4. Less Invasive By Pass Surgery Proves Economical In The Long Run
5. Epidural Mistakes Proves To Be Fatal Blunders
6. Combined Anti-Fever Drug Therapy Proves Unsafe for Childhood Fever
7. Drug Trial Proves Nightmare for British Indian Student
8. Naturopathic Care Proves Beneficial for TMD Pain
9. Medtronic Device Proves Effective in Parkinson’s Diseas
10. Large Community Spirometry Screening Proves Successful
11. Pregabalin Proves Durable Pain Relief Option for Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/13/2019)... ... June 13, 2019 , ... Hard money lenders like Monroe ... and the funds can also be provided quickly. If the documentation and collateral are ... are able to avoid the federal oversight involved with a traditional lender, which allows ...
(Date:6/13/2019)... ... 2019 , ... Many people with back pain that radiates down their legs ... widely misunderstood and so are its treatments, according to Kaliq Chang, MD, double board-certified ... , “Sciatica is commonly used to describe nerve-like pain traveling down the legs, often ...
(Date:6/13/2019)... ... June 13, 2019 , ... GlycoMark, Inc. ... at the American Diabetes Association (ADA) Scientific Sessions 2019 involving the GlycoMark test ... an SGLT-2 inhibitor. SGLT-2 inhibitors are used to lower glucose levels in patients ...
(Date:6/12/2019)... ... June 12, 2019 , ... In September of 2018, NVNA and Hospice ... and remote patient monitoring. Following its full-scale launch in March, NVNA has expanded its ... the beginning of 2019, NVNA has achieved an average all-cause hospital readmissions rate of ...
(Date:6/11/2019)... ... June 11, 2019 , ... ... and developmental disabilities and their families recently received the promise of a two-million-dollar ... grant, gifted by The Tomlinson Foundation, would allow TERI to complete phase two ...
Breaking Medicine News(10 mins):
(Date:6/12/2019)... ... June 12, 2019 , ... Through their Sidewalk Angels Foundation (SWA), Marisol ... importance of protecting your entire family from Lyme and other tick-borne diseases. We are ... fur we have. , Through this partnership SWA and GLA look to raise ...
(Date:6/11/2019)... ... , ... Today NASH kNOWledge hosted a Liver Disease Information ... Steatohepatitis (NASH) Day, a global effort in the fight against NASH. Community leaders ... what they can do to help. The event also included a pre-screening of ...
(Date:6/11/2019)... China, and SAN DIEGO (PRWEB) , ... June ... ... and fully integrated global Contract Development and Manufacturing Organization (CDMO) serving the global ... announced the appointment of Wei Chen, Ph.D as the company's new Chief Executive ...
Breaking Medicine Technology: